p38 MAP kinase as a therapeutic target in cardiovascular disease

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 2, 2004, Pages 149-154

  See, Fiona ^a,b   Kompa, A ^a,b   Krum, H ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FR 16753; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL STUDY; DATA ANALYSIS; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; ENTERITIS; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; STROKE; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 13344275779     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.08.024     Document Type: Review

References (21)

1. M. Zhao et al. Activation of the p38 MAP kinase pathway is required for foam cell formation from macrophages exposed to oxidized LDL Acta Pathol. Microbiol. Scand. 110 2002 458-468
2. Z.B. Lei et al. OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase Cardiovasc. Res. 53 2002 524-532
3. 2, p38 Kinase, and activator protein-1 in human aortic smooth muscle cells Cardiovasc. Res. 62 2004 185-193
4. Z. Wang et al. Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells J. Mol. Cell. Cardiol. 36 2004 49-56
5. K. MacKay D. Mochly-Rosen An inhibitor of p38 mitogen-activated protein kinase protects neonatal cardiac myocytes from ischemia J. Biol. Chem. 274 1999 6272-6279
6. R.A. Kaiser et al. Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo J. Biol. Chem. 279 2004 15524-15530
7. F. Gao et al. p38 MAPK inhibition reduces myocardial reperfusion injury via inhibition of endothelial adhesion molecule expression and blockade of PMN accumulation Cardiovasc. Res. 53 2002 414-422
8. X.L. Ma et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion Circulation 99 1999 1685-1691
9. D. Talmor et al. Activation of mitogen-activated protein kinases in human heart during cardiopulmonary bypass Circ. Res. 86 2002 1004-1007
10. N. Koike et al. Effects of adding p38 mitogen-activated protein-kinase inhibitor to celsior solution in canine heart transplantation from non-heart-beating donors Transplantation 77 2004 286-292
11. S.A. Cook et al. Activation of c-Jun N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease J. Mol. Cell. Cardiol. 31 1999 1429-1434
12. See F. et al. 2004 p38 Mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat J. Am. Coll. Cardiol. 44 1679-1689
13. J. Widder et al. Vascular endothelial dysfunction and superoxide anion production in heart failure are p38 MAP kinase-dependent Cardiovasc. Res. 63 2004 161-167
14. F.C. Barone et al. Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemia Med. Res. Rev. 21 2001 129-145
15. T.M. Behr et al. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction Circulation 104 2001 1292-1298
16. H. Ju et al. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension J. Pharmacol. Exp. Ther. 307 2003 932-938
17. S.R. Lee E.H. Lo Interactions between p38 mitogen-activated protein kinase and caspase-3 in cerebral endothelial cell death after hypoxia-reoxygenation Stroke 34 2003 2704-2709
18. C. Andrews et al. The MKK6-p38 MAPK pathway prolongs the cardiac contractile calcium transient, downregulates SERCA2, and activates NF-AT Cardiovasc. Res. 59 2003 46-56
19. P. Liao et al. p38 Mitogen-activated protein kinase mediates a negative inotropic effect in cardiac myocytes Circ. Res. 90 2002 190-196
20. J. Braz et al. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling J. Clin. Invest. 111 2003 1475-1486
21. L.E. Lemke et al. Decreased p38 MAPK activity in end-stage failing human myocardium: P38 MAPK [alpha] is the predominant isoform expressed in human heart J. Mol. Cell. Cardiol. 33 2001 1527-1540